Expion360 Inc (XPON) Stock Analysis
Verdict: AVOID
Extreme cash burn leaves ~5.8 months of runway, forcing ongoing share dilution that overshadows 74% speculative price spikes.
Investment score: 26/100
Analysis as of
Is Expion360 Inc stock worth reviewing? AI model thesis
The AI model views Expion360 as an avoid due to severe cash burn ($6.15M annually), short cash runway (~5.8 months), and continuous share dilution despite short-term technical surges.
7-factor investment score
- Valuation: 25/100 (weight 20%)
- Financial Health: 15/100 (weight 15%)
- Technical Momentum: 45/100 (weight 15%)
- Earnings Quality: 30/100 (weight 15%)
- Insider Sentiment: 30/100 (weight 10%)
- Analyst Consensus: 35/100 (weight 10%)
- Risk-Adjusted Return: 10/100 (weight 15%)
Expion360 Inc opportunities and risks
What speaks for XPON
- Revenue growth expanded 71.6% YoY to $9.65M in 2025.
What speaks against XPON
- Cash runway is limited to ~5.8 months based on 2025 FCF burn of -$6.15M.
Peers and competitors
| Ticker | P/E | P/S | EV/EBITDA | Gross margin | Net margin | FCF yield |
|---|---|---|---|---|---|---|
| XPON | n/a | 1.1x | n/a | 15.2% | -82.3% | -81.5% |
| CYBL | n/a | 1.1x | n/a | -64.5% | -502.4% | -46.2% |
| SDST | n/a | 0.0x | n/a | 0.0% | 0.0% | -143.9% |
| SUNE | n/a | 0.1x | n/a | 34.8% | -8.5% | -23.6% |
| GWSO | n/a | 0.0x | n/a | 0.0% | 0.0% | -2.4% |
| TOGI | n/a | 0.5x | n/a | 47.6% | -27.5% | -55.4% |
| Peer median | n/a | 0.1x | n/a | 0.0% | -8.5% | -46.2% |
Frequently asked questions about Expion360 Inc (XPON)
Is XPON stock a good investment?
The cached TradeMates AI model rates Expion360 Inc as AVOID with an investment score of 26/100. The AI model views Expion360 as an avoid due to severe cash burn ($6.15M annually), short cash runway (~5.8 months), and continuous share dilution despite short-term technical surges. This is algorithmic model output, not personal investment advice.
Is XPON stock a buy?
The TradeMates model verdict for XPON is AVOID with an investment score of 26/100. Treat this as a model signal to review, not a personal buy recommendation.